Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Division of General and Transplant Surgery, University of Pisa, Pisa, Italy.
J Gastrointest Surg. 2018 Oct;22(10):1804-1810. doi: 10.1007/s11605-018-3894-7. Epub 2018 Aug 13.
Approximately 30% of all pancreatic cancer patients have locally advanced (AJCC stage 3) disease. A sub-group of these patients-where the cancer only involves the celiac axis-may benefit from distal pancreatectomy with celiac axis resection (DP-CAR). Previous studies have shown that DP-CAR offers a survival benefit to a selected group of patients with otherwise unresectable pancreatic cancer, when performed by experienced pancreatic cancer treatment teams at high-volume centers. This article proposes a standardized approach to DP-CAR, including routine neoadjuvant (FOLFIRINOX) chemotherapy. This approach to selecting patients and performing DP-CAR has the potential to improve short-term outcomes and overall survival in selected patients, but it should be reserved for high-volume centers.
约 30%的胰腺癌患者存在局部晚期(AJCC 分期 3 期)疾病。这些患者中的亚组-其癌症仅累及腹腔干-可能受益于伴有腹腔干切除的胰体尾切除术(DP-CAR)。先前的研究表明,在经验丰富的胰腺肿瘤治疗团队于高容量中心进行手术时,对于其他情况下无法切除的胰腺癌的选定患者,DP-CAR 可提供生存获益。本文提出了一种 DP-CAR 的标准化方法,包括常规新辅助(FOLFIRINOX)化疗。这种选择患者并进行 DP-CAR 的方法有可能改善选定患者的短期结果和总生存期,但应将其保留给高容量中心。